article thumbnail

Cancer vaccine shows sustained improvement in survival rates

Drug Discovery World

Cancer vaccine mRNA-4157 (V940) in combination with Keytruda reduced the risk of recurrence or death by 49% in patients with resected high-risk melanoma, according to follow-up data presented at ASCO 2024. Ultimately it will contribute to survival rates improving continually over the next decades and more.” .”

Vaccine 147
article thumbnail

Vaccine monitoring crucial as SARS-CoV-2 evolves, say researchers

Drug Discovery World

UK researchers have highlighted the importance of continued surveillance of emerging SARS-CoV-2 variants and vaccine performance as the virus continues to evolve. The researchers found that both vaccines generated neutralising antibodies against the most recent strain of Omicron, BA.2.86. strains after their booster vaccination.

Vaccine 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA approves RSV vaccine to protect babies from birth

Drug Discovery World

The US Food and Drug Administration (FDA) has approved the first vaccine for pregnant individuals to prevent respiratory syncytial virus (RSV) in infants.

article thumbnail

AI identifies drug candidates for respiratory syncytial virus

Drug Discovery World

Potential new drug candidates have been identified by a respiratory syncytial virus (RSV) artificial intelligence programme, as health officials warn of a “tripledemic” of SARS-CoV-2, influenza and RSV. . The post AI identifies drug candidates for respiratory syncytial virus appeared first on Drug Discovery World (DDW).

Virus 130
article thumbnail

Covid-19 vaccine less effective in the immunocompromised 

Drug Discovery World

A new study in the US has revealed that the Covid-19 vaccine is less effective in people with weakened immune systems. . The research from the Centers for Disease Control and Prevention’s VISION Network analysed real-world data on mRNA vaccine effectiveness during Omicron BA.4 5 predominance for immunocompromised adults. .

Vaccine 130
article thumbnail

European Commission authorises GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for older adults

The Pharma Data

This is the first time an RSV vaccine for older adults has been granted European Marketing Authorisation. This authorisation for Arexvy means eligible adults can be vaccinated against RSV disease for the first time, reinforcing GSK’s long history of vaccine innovation. The vaccine was generally well tolerated.

Virus 40
article thumbnail

Nearly 700,000 US hospitalizations and 110,000 deaths prevented from the Pfizer-BioNTech COVID-19 vaccine

The Pharma Data

The profound health and economic impact of the Pfizer-BioNTech vaccine during its first year of rollout in the US is described in detail in a new study in the peer-reviewed Journal of Medical Economics. It is estimated that in 2021 the vaccine, the most widely used against COVID-19 in the US, prevented 8.7

Vaccine 52